Measurement of the interaction of aqueous copper(II) with a model amyloid-β protein fragment — Interference from buffers

2011 ◽  
Vol 89 (12) ◽  
pp. 1429-1444 ◽  
Author(s):  
Michael H. Benn ◽  
Arvi Rauk ◽  
Thomas W. Swaddle

For the formation of a complex of Cu2+ with the amyloid-β (Aβ) proxy N-α-dihydrourocanylhistamine (L) in unbuffered aqueous solution (pH ∼ 5.7, 25.0 °C), UV spectrophotometric measurements give a stability constant of 3.8 × 105 L mol–1. This stability constant is within the lower limit of the range of stability constants reported in the literature for complexes of Aβ with Cu2+ — as expected, in view of the smaller number of coordination sites in L. Computer modeling indicates that the Cu2+–L complex is CuL(H2O)22+, with terdentate L bound to Cu2+ via two Nπ atoms and the O atom of the peptide link. Attempts to make stability constant measurements for Cu2+ with L in aqueous solution buffered with Tris/TrisH+/ClO4– to pH near 7.2 were unsuccessful because the Tris base when in large excess over CuL2+ promoted its dissociation to Cu2+ + L by scavenging free Cu2+ as Cu(Tris)(TrisH–1)+, or when in roughly equimolar concentrations formed a ternary adduct, CuL(Tris)2+. The interactions of Cu2+ with Tris buffer were re-examined spectrophotometrically and with the aid of computations that show that the most stable Cu2+–Tris complexes are the syn- and anti-isomers of Cu(Tris)22+, but in the experimental pH ranges these are present as Cu(Tris)(TrisH–1)+. Since Cu2+(aq) is strongly complexed by almost any base capable of forming a buffer system with near-physiological pH, stability constants reported for Cu2+–Aβ complexes in any buffer solution should be regarded with skepticism unless interactions of the buffer with Cu2+ and with CuAβ2+ are taken quantitatively into account. Moreover, in vivo, biological buffers will reduce the physiological importance of Aβ–Cu2+ complexes by competing with Aβ for Cu2+.

2009 ◽  
Vol 6 (s1) ◽  
pp. S496-S500
Author(s):  
K. S. Parikh ◽  
R. M. Patel ◽  
K. N. Patel

The reagent 2-hydroxy-4-n-butoxy-5-bromopropiophenone thiosemicarbazone (HBBrPT) has been used for the determination of Cd(II) by using spectrophotometric method. The reagent HBBrPT gave an intense yellow colour with Cd(II) solution in basic medium. The maximum absorbance was observed at 440 nm, in basic buffer solution (pH 10.00). The molor absorptivity and Sandell’s sensitivity of Cd(II)-HBBrPT complex were 4035 mol-1cm-1and 0.02765 μg cm-2respectively. The stability constant of 1:2 Cd(II)-HBBrPT complex was 8.46×106. The effect of various iron was also studied.


Nature ◽  
2002 ◽  
Vol 416 (6880) ◽  
pp. 535-539 ◽  
Author(s):  
Dominic M. Walsh ◽  
Igor Klyubin ◽  
Julia V. Fadeeva ◽  
William K. Cullen ◽  
Roger Anwyl ◽  
...  

Pharmaceutics ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 79
Author(s):  
Maxim Morin ◽  
Sebastian Björklund ◽  
Skaidre Jankovskaja ◽  
Kieran Moore ◽  
Maria Begoña Delgado-Charro ◽  
...  

Non-invasive methods for early diagnosis of skin cancer are highly valued. One possible approach is to monitor relevant biomarkers such as tryptophan (Trp) and kynurenine (Kyn), on the skin surface. The primary aim of this in vitro investigation was, therefore, to examine whether reverse iontophoresis (RI) can enhance the extraction of Trp and Kyn, and to demonstrate how the Trp/Kyn ratio acquired from the skin surface reflects that in the epidermal tissue. The study also explored whether the pH of the receiver medium impacted on extraction efficiency, and assessed the suitability of a bicontinuous cubic liquid crystal as an alternative to a simple buffer solution for this purpose. RI substantially enhanced the extraction of Trp and Kyn, in particular towards the cathode. The Trp/Kyn ratio obtained on the surface matched that in the viable skin. Increasing the receiver solution pH from 4 to 9 improved extraction of both analytes, but did not significantly change the Trp/Kyn ratio. RI extraction of Trp and Kyn into the cubic liquid crystal was comparable to that achieved with simple aqueous receiver solutions. We conclude that RI offers a potential for non-invasive sampling of low-molecular weight biomarkers and further investigations in vivo are therefore warranted.


2020 ◽  
pp. 1-12 ◽  
Author(s):  
Yingxia Liang ◽  
Frank Raven ◽  
Joseph F. Ward ◽  
Sherri Zhen ◽  
Siyi Zhang ◽  
...  

2008 ◽  
Vol 64 (6) ◽  
pp. 618-627 ◽  
Author(s):  
Zhongcong Xie ◽  
Deborah J. Culley ◽  
Yuanlin Dong ◽  
Guohua Zhang ◽  
Bin Zhang ◽  
...  

1996 ◽  
Vol 17 (4) ◽  
pp. S68
Author(s):  
C.B. Eckman ◽  
C.-M. Prada ◽  
A. Fauq ◽  
S.G. Younkin

Author(s):  
Kie Honjo ◽  
Sandra E. Black ◽  
Nicolaas P. L. G. Verhoeff

Alzheimer's disease (AD), considered the commonest neurodegenerative cause of dementia, is associated with hallmark pathologies including extracellular amyloid-β protein (Aβ) deposition in extracellular senile plaques and vessels, and intraneuronal tau deposition as neurofibrillary tangles. Although AD is usually categorized as neurodegeneration distinct from cerebrovascular disease (CVD), studies have shown strong links between AD and CVD. There is evidence that vascular risk factors and CVD may accelerate Aβ 40-42 production/ aggregation/deposition and contribute to the pathology and symptomatology of AD. Aβ deposited along vessels also causes cerebral amyloid angiopathy. Amyloid imaging allowsin vivodetection of AD pathology, opening the way for prevention and early treatment, if disease-modifying therapies in the pipeline show safety and efficacy. In this review, we review the role of vascular factors and Aβ, underlining that vascular risk factor management may be important for AD prevention and treatment.


2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Jing Di ◽  
Ibrar Siddique ◽  
Zizheng Li ◽  
Ghattas Malki ◽  
Simon Hornung ◽  
...  

Abstract Background Molecular tweezers (MTs) are broad-spectrum inhibitors of abnormal protein aggregation. A lead MT, called CLR01, has been demonstrated to inhibit the aggregation and toxicity of multiple amyloidogenic proteins in vitro and in vivo. Previously, we evaluated the effect of CLR01 in the 3 × Tg mouse model of Alzheimer’s disease, which overexpresses mutant human presenilin 1, amyloid β-protein precursor, and tau and found that subcutaneous administration of the compound for 1 month led to a robust reduction of amyloid plaques, neurofibrillary tangles, and microgliosis. CLR01 also has been demonstrated to inhibit tau aggregation in vitro and tau seeding in cell culture, yet because in Alzheimer’s disease (AD) and in the 3 × Tg model, tau hyperphosphorylation and aggregation are thought to be downstream of Aβ insults, the study in this model left open the question whether CLR01 affected tau in vivo directly or indirectly. Methods To determine if CLR01 could ameliorate tau pathology directly in vivo, we tested the compound similarly using the P301S-tau (line PS19) mouse model. Mice were administered 0.3 or 1.0 mg/kg per day CLR01 and tested for muscle strength and behavioral deficits, including anxiety- and disinhibition-like behavior. Their brains then were analyzed by immunohistochemical and biochemical assays for pathological forms of tau, neurodegeneration, and glial pathology. Results CLR01 treatment ameliorated muscle-strength deterioration, anxiety-, and disinhibition-like behavior. Improved phenotype was associated with decreased levels of pathologic tau forms, suggesting that CLR01 exerts a direct effect on tau in vivo. Limitations of the study included a relatively short treatment period of the mice at an age in which full pathology is not yet developed. In addition, high variability in this model lowered the statistical significance of the findings of some outcome measures. Conclusions The findings suggest that CLR01 is a particularly attractive candidate for the treatment of AD because it targets simultaneously the two major pathogenic proteins instigating and propagating the disease, amyloid β-protein (Aβ), and tau, respectively. In addition, our study suggests that CLR01 can be used for the treatment of other tauopathies in the absence of amyloid pathology.


1981 ◽  
Vol 34 (12) ◽  
pp. 2549 ◽  
Author(s):  
H Stunzi

The reactions in aqueous solution between cupric ion and water-soluble derivatives of the antiviral drug methisazone (1-methylisatin β-thiosemicarbazone, mibt) have been investigated. Alkalimetric titrations and n.m.r. experiments showed that 5-sulfonatoisatin β-thiosemicarbazone, sibt (3), its 1-methyl derivative, msibt (4), and also p-sulfonatobenzaldehyde thiosemicarbazone, sbat (5), reduce cupric ion and form copper(I) complexes. Stability constants were obtained from measurements of pH and pCu+ on solutions of copper(II) nitrate and excess ligand (I = 0.15 M KNO3, at 37�). The pCu+ values were obtained with an ORION solid state copper electrode. At pH 6-7.5 and moderate excess of ligand, polymeric complexes with an approximate 1 : 1 copper(1)-to-ligand ratio are formed: CunLn or CunLn+,H with n > 6. Monomeric complexes CuL23- predominate at higher pH and in the presence of a more than twentyfold excess of ligand. The stability constants log β2 are 17.9 for sibt, 18.5 for msibt and 19.8 for sbat. At physiological pH (7.4), the order of stability is msibt > sibt & sbat, with conditional stability constants log β2 = 16.2, 15.7 and 13.4, respectively. Comparison with penicillamine shows that some in vivo complexation of copper(I) by methisazone may be possible. On the other hand, a histidinato-copper(II) complex is formed in the presence of histidine.


Sign in / Sign up

Export Citation Format

Share Document